ADVERTISEMENT

Admin's Picks

ADVERTISEMENT
ADVERTISEMENT
Host Sonu
ADVERTISEMENT

Essentials of First In Human Studies: Planning and Execution

First In Human (FIH) studies are critical early-phase clinical trials that mark the transition of a new drug or treatment from preclinical research to human testing. These studies are essential for assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of new investigational products. Planning and executing FIH studies require meticulous attention to detail, adherence to regulatory requirements, and robust risk management. This article outlines the key elements involved in the planning and execution of FIH studies.

1. Preclinical Preparation

Objective: Ensure that sufficient preclinical data supports the initiation of FIH studies.

  • Toxicology Studies: Conduct comprehensive toxicology studies in relevant animal models to determine the safety profile of the investigational product. These studies should assess acute, subacute, and chronic toxicity, as well as potential genotoxicity, carcinogenicity, and reproductive toxicity.
  • Pharmacokinetics (PK) and Pharmacodynamics (PD): Characterize the pharmacokinetics (absorption, distribution, metabolism, and excretion) and pharmacodynamics (biological effects) of the drug in animal models to predict human responses.
  • Dose Selection: Establish the starting dose for FIH studies using data from preclinical studies. The No Observed Adverse Effect Level (NOAEL) from animal studies is typically used to calculate the safe starting dose for humans, applying appropriate safety factors.
  • Good Laboratory Practice (GLP) Compliance: Ensure that all preclinical studies are conducted in compliance with GLP regulations to ensure data integrity and reliability.

2. Regulatory and Ethical Considerations

Objective: Obtain regulatory and ethical approvals to ensure compliance and protect participant safety.

  • Investigational New Drug (IND) Application: Submit an IND application to the relevant regulatory authority (e.g., FDA in the United States) that includes preclinical data, study protocols, and information about the investigational product. The application should demonstrate that the product is reasonably safe for initial human testing.
  • Ethics Committee/Institutional Review Board (IRB) Approval: Obtain approval from an ethics committee or IRB to ensure that the study is ethically sound and that participants’ rights and welfare are protected.
  • Informed Consent: Develop a comprehensive informed consent form that clearly explains the study’s purpose, procedures, risks, benefits, and participant rights. Ensure that participants provide informed consent voluntarily before enrollment.

3. Study Design and Protocol Development

Objective: Develop a robust study design and protocol to ensure the collection of meaningful and reliable data.

  • Study Objectives: Define the primary and secondary objectives of the study, focusing on safety, tolerability, pharmacokinetics, and pharmacodynamics.
  • Study Population: Select an appropriate study population, typically healthy volunteers or patients with the target condition, depending on the nature of the investigational product.
  • Dose Escalation Plan: Develop a dose escalation plan to gradually increase the dose in subsequent cohorts based on safety and tolerability data from earlier cohorts. Use adaptive design principles to modify the study based on interim data.
  • Safety Monitoring: Establish a Data Monitoring Committee (DMC) or Safety Review Committee (SRC) to review safety data regularly and make recommendations about dose escalation, modification, or study continuation.
  • Endpoints and Assessments: Define clear endpoints and assessments, including clinical, laboratory, and imaging evaluations. Ensure that these assessments are sensitive enough to detect potential safety signals and pharmacodynamic effects.

4. Site Selection and Preparation

Objective: Ensure that study sites are adequately prepared to conduct the FIH study.

  • Site Selection: Choose experienced clinical sites with the necessary infrastructure, equipment, and trained personnel to conduct FIH studies. Consider the site’s track record in early-phase clinical trials and its ability to recruit participants.
  • Site Training: Provide comprehensive training to site staff on the study protocol, procedures, and safety monitoring. Ensure that staff are familiar with Good Clinical Practice (GCP) guidelines and the specific requirements of FIH studies.
  • Logistics and Supplies: Ensure that the investigational product, lab supplies, and other necessary materials are available at the study site. Plan for the timely delivery and proper storage of these materials.

5. Participant Recruitment and Enrollment

Objective: Recruit and enroll participants in a manner that ensures their safety and compliance with the study protocol.

  • Recruitment Strategy: Develop a recruitment strategy that includes outreach to potential participants, advertising, and engagement with patient advocacy groups if applicable. Ensure that recruitment materials are clear, accurate, and compliant with regulatory guidelines.
  • Screening and Eligibility: Implement a rigorous screening process to ensure that participants meet the inclusion and exclusion criteria. Conduct thorough medical evaluations, including physical exams, laboratory tests, and medical history reviews.
  • Informed Consent Process: Conduct the informed consent process carefully, providing participants with ample time to ask questions and make informed decisions. Document the consent process meticulously.

6. Study Conduct and Safety Monitoring

Objective: Conduct the study according to the protocol while ensuring participant safety and data integrity.

  • Dosing Procedures: Administer the investigational product according to the protocol, ensuring accurate dosing and monitoring. Use qualified personnel to handle and administer the product.
  • Adverse Event Monitoring: Monitor participants closely for adverse events (AEs) and serious adverse events (SAEs). Implement procedures for immediate reporting and management of AEs/SAEs.
  • Pharmacokinetic and Pharmacodynamic Sampling: Collect blood, urine, or other biological samples at specified time points to assess pharmacokinetics and pharmacodynamics. Ensure proper sample handling, processing, and storage.
  • Data Collection and Management: Use electronic data capture (EDC) systems to collect and manage study data. Ensure data accuracy, completeness, and compliance with regulatory requirements.

7. Data Analysis and Reporting

Objective: Analyze and report study data to determine the safety and preliminary efficacy of the investigational product.

  • Data Analysis Plan: Develop a statistical analysis plan (SAP) that outlines the methods for analyzing safety, pharmacokinetic, and pharmacodynamic data. Ensure that the SAP is finalized before database lock.
  • Interim Analysis: Conduct interim analyses as specified in the protocol to assess safety and make informed decisions about dose escalation and study continuation.
  • Final Analysis and Reporting: Perform final data analysis after study completion. Prepare a comprehensive clinical study report (CSR) that includes all relevant data, analyses, and interpretations.
  • Regulatory Submission: Submit the CSR and other required documents to regulatory authorities to support further clinical development.

Conclusion

Planning and executing First In Human studies require a detailed, systematic approach to ensure the safety of participants and the collection of high-quality data. By adhering to regulatory guidelines, implementing robust safety monitoring, and employing best practices in study design and conduct, researchers can successfully navigate the complexities of FIH studies. These early-phase trials are crucial for advancing new therapies from the laboratory to clinical application, ultimately contributing to the development of safe and effective treatments for patients.

ADVERTISEMENT

CHECK OUT OUR LATEST

ARTICLES
Scroll to Top